Health Economics›Breast cancer›Metastatic disease first-line therapy

Metastatic disease first-line therapy

Breast cancer · 49 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 40 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel and Pembrolizumab Variant #01	TNBC	R 127 697	28d	7.8 mo	23.0 mo	9	R 1 149 274 PFS proxy	2
nab-Paclitaxel and Atezolizumab Variant #01	TNBC	R 89 466	28d	—	21.0 mo	—	—	1
Carboplatin and Gemcitabine (GCb) and Pembrolizumab Variant #01	TNBC	R 85 650	21d	7.8 mo	23.0 mo	12	R 1 027 803 PFS proxy	2
Paclitaxel and Pembrolizumab Variant #01	TNBC	R 83 860	28d	7.8 mo	23.0 mo	9	R 754 739 PFS proxy	2
nab-Paclitaxel monotherapy Variant #01	TNBC	R 45 710	28d	6.9 mo	18.7 mo	8	R 365 679 PFS proxy	5
nab-Paclitaxel and Toripalimab Variant #01 Partial	TNBC	R 38 092	21d	8.4 mo	32.8 mo	13	R 495 190 PFS proxy	2
Lapatinib and Letrozole Variant #01	ER\|ERBB2	R 38 048	28d	8.2 mo	—	9	R 342 431 PFS proxy	1
Fulvestrant and Ribociclib Variant #01	ER	R 37 135	28d	20.5 mo	60.7 mo	23	R 854 110 PFS proxy	3
Exemestane, Lapatinib, Trastuzumab Variant #01	ER\|ERBB2	R 29 940	21d	11.0 mo	—	16	R 479 043 PFS proxy	1
Lapatinib, Letrozole, Trastuzumab Variant #01	ER\|ERBB2	R 29 554	21d	11.0 mo	—	16	R 472 867 PFS proxy	1
Anastrozole, Lapatinib, Trastuzumab Variant #01	ER\|ERBB2	R 29 395	21d	11.0 mo	—	16	R 470 326 PFS proxy	1
Letrozole and Bevacizumab Variant #01	ER	R 28 901	21d	19.8 mo	—	29	R 838 139 PFS proxy	2
Letrozole and Ribociclib Variant #01	ER	R 21 181	28d	25.3 mo	63.9 mo	28	R 593 065 PFS proxy	2
Paclitaxel and Trastuzumab (TH) Variant #01	ER\|ERBB2	R 16 575	21d	13.7 mo	24.0 mo	20	R 331 509 PFS proxy	8
Abemaciclib and Letrozole Variant #01	ER	R 16 291	28d	28.2 mo	66.8 mo	31	R 505 008 PFS proxy	3
Abemaciclib and Anastrozole Variant #01	ER	R 16 079	28d	28.2 mo	66.8 mo	31	R 498 443 PFS proxy	3
Cisplatin and Gemcitabine (GC) Variant #34	TNBC	R 15 338	56d	7.6 mo	—	5	R 76 690 PFS proxy	1
Vinorelbine and Trastuzumab (VH) Variant #01	ER\|ERBB2	R 14 392	28d	14.8 mo	—	17	R 244 663 PFS proxy	1
Docetaxel and Trastuzumab (TH) Variant #01	ER\|ERBB2	R 12 507	21d	12.5 mo	40.8 mo	19	R 237 632 PFS proxy	9
Capecitabine and Trastuzumab (XH) Variant #02	ER\|ERBB2	R 11 671	21d	9.9 mo	—	15	R 175 058 PFS proxy	2
Anastrozole and Fulvestrant Variant #01	ER	R 11 043	28d	15.0 mo	47.7 mo	17	R 187 723 PFS proxy	2
Toremifene and Trastuzumab Variant #01	ER\|ERBB2	R 10 993	21d	19.2 mo	—	28	R 307 804 PFS proxy	1
Fulvestrant monotherapy Variant #03	ER	R 10 883	28d	14.4 mo	44.8 mo	16	R 174 135 PFS proxy	6
Letrozole and Trastuzumab Variant #01	ER\|ERBB2	R 10 716	21d	12.4 mo	—	18	R 192 883 PFS proxy	2
Anastrozole and Trastuzumab Variant #01	ER\|ERBB2	R 10 557	21d	5.6 mo	—	9	R 95 012 PFS proxy	3
Tamoxifen and Trastuzumab Variant #01	ER\|ERBB2	R 10 540	21d	19.2 mo	—	28	R 295 121 PFS proxy	1
Goserelin monotherapy Variant #04	ER	R 10 511	84d	—	—	—	—	—
Exemestane and Trastuzumab Variant #01	ER\|ERBB2	R 10 464	21d	12.4 mo	—	18	R 188 354 PFS proxy	2
Letrozole and Palbociclib Variant #01	ER	R 10 226	28d	21.5 mo	53.9 mo	24	R 245 435 PFS proxy	4
Mitoxantrone and Vinorelbine (MV) Variant #01	—	R 4 670	21d	—	—	—	—	—
Carboplatin and Gemcitabine (GCb) Variant #01	TNBC	R 3 663	21d	5.5 mo	11.9 mo	8	R 29 304 PFS proxy	3
Capecitabine and Docetaxel (TX) Variant #01	TNBC	R 3 056	21d	8.4 mo	—	13	R 39 725 PFS proxy	1
Exemestane monotherapy Variant #01	ER	R 2 846	90d	9.9 mo	45.1 mo	4	R 11 385 PFS proxy	3
Goserelin and Tamoxifen Variant #01	ER	R 2 764	28d	13.0 mo	48.0 mo	15	R 41 467 PFS proxy	2
Paclitaxel monotherapy Variant #46	TNBC	R 2 220	28d	6.9 mo	20.5 mo	8	R 17 756 PFS proxy	16
STAMP-I Variant #01 Partial	—	R 2 164	—	—	—	—	—	—
FAC Variant #01	TNBC	R 1 045	28d	8.0 mo	17.3 mo	9	R 9 409 PFS proxy	3
CAV Variant #01	—	R 760	21d	—	~7.6 mo	—	—	1
VAP Variant #01	—	R 684	21d	—	—	—	—	—
Toremifene monotherapy Variant #01	ER	R 494	28d	—	—	—	—	—
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	TNBC	R 449	21d	—	32.8 mo	—	—	1
Tamoxifen monotherapy Variant #06	ER	R 410	28d	6.8 mo	19.9 mo	8	R 3 279 PFS proxy	5
Letrozole monotherapy Variant #01	ER\|ERBB2	R 371	28d	14.5 mo	51.3 mo	16	R 5 934 PFS proxy	15
Letrozole monotherapy Variant #01	ER	R 371	28d	14.5 mo	51.3 mo	16	R 5 934 PFS proxy	15
Gemcitabine and Paclitaxel N/A - secondary systemic drug	TNBC	R 263	28d	6.5 mo	18.6 mo	8	R 2 108 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	TNBC	R 243	28d	8.2 mo	32.6 mo	9	R 2 188 PFS proxy	5
Anastrozole monotherapy Variant #01	ER\|ERBB2	R 159	28d	13.8 mo	42.7 mo	16	R 2 546 PFS proxy	11
Anastrozole monotherapy Variant #01	ER	R 159	28d	13.8 mo	42.7 mo	16	R 2 546 PFS proxy	11
Tamoxifen and Prednisolone Variant #01	ER	R 151	28d	—	—	—	—	—

49 of 49 regimens shown